These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 54337)
21. Antibacterial and antitoxin responses in the serum and milk of cholera patients. Majumdar AS; Dutta P; Dutta D; Ghose AC Infect Immun; 1981 Apr; 32(1):1-8. PubMed ID: 7216479 [TBL] [Abstract][Full Text] [Related]
22. Active and passive immunization in the adult rabbit ileal loop model as an assay for production of antitoxin immunity by cholera vaccines. Mosley WH; Ahmed A J Bacteriol; 1969 Oct; 100(1):547-9. PubMed ID: 5344118 [TBL] [Abstract][Full Text] [Related]
23. Role of local IgA antitoxin-producing cells for intestinal protection against cholera toxin challenge. Lycke N; Bromander AK; Holmgren J Int Arch Allergy Appl Immunol; 1989; 88(3):273-9. PubMed ID: 2785966 [TBL] [Abstract][Full Text] [Related]
24. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Levine MM; Nalin DR; Craig JP; Hoover D; Bergquist EJ; Waterman D; Holley HP; Hornick RB; Pierce NP; Libonati JP Trans R Soc Trop Med Hyg; 1979; 73(1):3-9. PubMed ID: 442179 [TBL] [Abstract][Full Text] [Related]
25. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge. Kundu J; Mazumder R; Srivastava R; Srivastava BS FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752 [TBL] [Abstract][Full Text] [Related]
26. Induction of a mucosal antitoxin response and its role in immunity to experimental canine cholera. Pierce NF; Cray WC; Sircar BK Infect Immun; 1978 Jul; 21(1):185-93. PubMed ID: 711314 [TBL] [Abstract][Full Text] [Related]
27. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. Liang XP; Lamm ME; Nedrud JG J Immunol; 1988 Sep; 141(5):1495-501. PubMed ID: 2842395 [TBL] [Abstract][Full Text] [Related]
28. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Viret JF; Favre D; Wegmüller B; Herzog C; Que JU; Cryz SJ; Lang AB Infect Immun; 1999 Jul; 67(7):3680-5. PubMed ID: 10377160 [TBL] [Abstract][Full Text] [Related]
30. Vibriolytic IgG immunocyte response of mice after primary and secondary immunization with cholera somatic antigens. Friedman H Immunology; 1975 Aug; 29(2):283-99. PubMed ID: 51000 [TBL] [Abstract][Full Text] [Related]
31. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. Glass RI; Svennerholm AM; Khan MR; Huda S; Huq MI; Holmgren J J Infect Dis; 1985 Feb; 151(2):236-42. PubMed ID: 3968450 [TBL] [Abstract][Full Text] [Related]
32. Experimental studies on cholera immunization. 1. The response of neutralizing and vibriocidal antibodies in rabbits after immunization with culture filtrate material from V. cholerae. Holmgren J; Svennerholm AM; Ouchterlony O Acta Pathol Microbiol Scand B Microbiol Immunol; 1972; 80(4):489-96. PubMed ID: 4509186 [No Abstract] [Full Text] [Related]
33. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098 [TBL] [Abstract][Full Text] [Related]
34. Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera. Kaisar MH; Bhuiyan MS; Akter A; Saleem D; Iyer AS; Dash P; Hakim A; Chowdhury F; Khan AI; Calderwood SB; Harris JB; Ryan ET; Qadri F; Charles RC; Bhuiyan TR mSphere; 2021 Apr; 6(2):. PubMed ID: 33910997 [TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia. Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522 [TBL] [Abstract][Full Text] [Related]
36. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Liang W; Wang S; Yu F; Zhang L; Qi G; Liu Y; Gao S; Kan B Infect Immun; 2003 Oct; 71(10):5498-504. PubMed ID: 14500467 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines. Cryz SJ; Fürer E; Germanier R Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478 [TBL] [Abstract][Full Text] [Related]
38. Strong biotype and serotype cross-protective antibacterial and antitoxic immunity in rabbits after cholera infection. Lycke N; Svennerholm AM; Holmgren J Microb Pathog; 1986 Aug; 1(4):361-71. PubMed ID: 3508492 [TBL] [Abstract][Full Text] [Related]
39. Antitoxic immunity in experimental cholera: comparison of immunity induced perorally and parenterally in mice. Fujita K; Finkelstein RA J Infect Dis; 1972 Jun; 125(6):647-55. PubMed ID: 5037016 [No Abstract] [Full Text] [Related]
40. Immunity to experimental cholera. III. Enhanced duration of protection after sequential parenteral-oral administration of toxoid to dogs. Pierce NF; Sack RB; Sircar BK J Infect Dis; 1977 Jun; 135(6):888-96. PubMed ID: 864285 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]